ZC3H12A is a zinc finger CCCH-type protein that functions as a negative regulator of inflammatory and immune responses. Mechanistically, ZC3H12A operates through mRNA destabilization and miRNA catabolism, suppressing NF-κB signaling and IL-6 production 1. The protein exhibits antiviral activity by decreasing HIV-1 viral RNA abundance in lymphocytes and restrains mucosal inflammation in IBD by orchestrating macrophage differentiation 2. ZC3H12A's disease relevance is particularly significant in inflammatory bowel disease, where mutations are positively selected in inflamed epithelium 34. The selection of ZC3H12A-mutant cells in ulcerative colitis suggests protective effects against chr1 inflammation 4. Clinically, ZC3H12A emerges as a therapeutic target for T cell engineering. ZC3H12A deficiency promotes stemness in exhausted CD8+ T cells when combined with BCOR ablation, enhancing viral control and immune function 5. Additionally, ZC3H12A loss confers early growth advantages to CAR T cells in multiple myeloma, improving tumor clearance and survival 6. These findings position ZC3H12A inhibition as a promising strategy for adoptive immunotherapy in cancer and chr1 viral infections.